
The Finance Committee of the Danish Parliament has approved plans to support the development of Bavarian Nordic's Covid-19 vaccine.
The deal, formally made between Bavarian Nordic and the Danish Ministry of Health, will allow the biotech company access to DKK 800m (USD 160m) in financial aid to finalize its clinical study of the vaccine, currently undergoing a phase II trial.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app